Breast cancers are complex tumors with a great spectrum of clinical and pathological features and diverse responses to available treatments. More studies are needed to standardize its assessment methods, determine more robust cut-off values, and evaluate its associations with prognostic features of breast cancer.īreast cancer is the most common neoplasm among women all over the world, and consequently, is associated with considerable morbidity and mortality. Nevertheless, in our study, MCM6 was superior to Ki-67 in exhibiting correlations with the mitotic grade, tubule formation, and nuclear grades. However, this study was unable to prove the superiority of MCM6 in differentiating between molecular subtypes compared to the Ki-67 score. MCM6 can differentiate luminal A and luminal B subtypes and is correlated with mitotic counts. Similarly, higher MCM6 scores were observed among samples with more advanced nuclear grades, tubule formation, and overall grades. Besides, MCM6 scores were higher for certain subtypes with more aggressive behaviors, such as hormone receptor (HR)-negative disease, and human epidermal growth factor receptor 2 (HER2)-enriched and triple-negative breast cancers, as there was a significantly higher MCM6 mean score in the HR-negative in comparison to the luminal breast cancers ( P < 0.001). Compared to the luminal A subtype, luminal B exhibited a higher MCM6 score ( P = 0.01). However, the Ki-67 score could not discriminate subgroups of the mitotic index and nuclear pleomorphism. Moreover, the MCM6 score exhibited a significant correlation with the mitotic count ( P < 0.001). MCM6 could discriminate between various categories of histologic grades, tubule formation, mitotic indices, and nuclear pleomorphism ( P = 0.002 for tubule formation and P < 0.001 for other). Relevant clinical information was retrieved from the Cancer Institute database. We performed a retrospective, cross-sectional study on 124 samples of breast cancer and 40 samples of normal breast tissue. Due to the limitations in the assessment and expression of Ki-67, we hypothesized that minichromosome maintenance protein 6 (MCM6) might be taken as a surrogate marker to differentiate molecular subtypes and aid in more precise grading of tumors. ![]() The distinction between the luminal A and luminal B subtypes is mainly based on the cellular proliferation indices and is assessed by the Ki-67 scoring. Currently, breast cancers are divided into four major molecular subtypes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |